madman
Super Moderator
LONG-TERM TESTOSTERONE TREATMENT IMPROVES LIVER FUNCTION PARAMETERS IN MEN WITH FUNCTIONAL HYPOGONADISM: REAL-WORLD DATA FROM A REGISTRY (2022)
Ahmad Haider, Karim Haider, Farid Saad, Gheorghe Doros, Abdulmaged Traish, Private Urology Practice, Bremerhaven, Germany Consultant, Bayer AG, Berlin, Germany Research Department, Guld Medical University, Ajman, UAE Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA
Introduction and Objectives: The prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with hypogonadism is high. Most of these patients are overweight or obese.
Methods: In a registry of 796 men with symptomatic functional hypogonadism, 394 men (49.5%) received testosterone therapy (TTh) by testosterone undecanoate (TU) injections of 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported. Fatty liver index (FLI) was calculated using the formula by Bedogni.
Results: Mean age at baseline: 60.9±6.0 years (T-group: 58.5±6.3, CTRL: 63.2±4.8). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years. γ-GT (U/L) decreased from 45.3±26.2 to 21.1±6.8 in the T-group and increased from 34.8±11.3 to 62.0±6.9 in CTRL (p<0.0001 for both).
*Triglycerides decreased from 3.2±0.6 to 2.2±0.1 in the T-group and increased from 3.0±0.5 to 3.7±0.6 in
CTRL (p<0.0001 for both).
*Waist circumference (cm) decreased from 110.9±13.7 to 96.1±5.1 in the T- group (p<0.0001) and increased in CTRL from 111.0±11.8 to 114.3±8.3 (p<0.0001).
*BMI (kg/m²) decreased from 34.2±5.4 to 27.5±2.4 in the T-group (p<0.0001) and increased in CTRL from 30.5±4.4 to 31.6±3.4 (p<0.0001).
*AST (U/L) decreased from 39.7±15.1 to 20.7±2.0 in the T-group and increased from 26.9±8.3 to 52.7±9.8 in CTRL (p<0.0001 for both).
*ALT (U/L) decreased from 42.7±14.9 to 24.6±2.3 in the T-group and increased from 31.1±8.6 to 58.6±12.0 in CTRL (p<0.0001 for both).
*FLI decreased from 89.9±11.0 to 57.0±13.0 in the T-group and increased from 84.3±13.4 to 94.2±5.2 in CTRL (p<0.0001 for both).
Conclusion: Long-term testosterone therapy in men with functional hypogonadism improved surrogate parameters of liver function indicating an improvement in NAFLD. All parameters deteriorated in untreated controls.
Ahmad Haider, Karim Haider, Farid Saad, Gheorghe Doros, Abdulmaged Traish, Private Urology Practice, Bremerhaven, Germany Consultant, Bayer AG, Berlin, Germany Research Department, Guld Medical University, Ajman, UAE Department of Epidemiology and Statistics, Boston University School of Public Health, Boston, MA, USA Department of Biochemistry and Department of Urology, Boston University School of Medicine, Boston, MA, USA
Introduction and Objectives: The prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with hypogonadism is high. Most of these patients are overweight or obese.
Methods: In a registry of 796 men with symptomatic functional hypogonadism, 394 men (49.5%) received testosterone therapy (TTh) by testosterone undecanoate (TU) injections of 1000mg/12weeks following an initial 6-week interval (T-group). 402 men opted against TTh and served as controls (CTRL). 13-year data are presented. Means and standard deviations of absolute measures over 13 years are reported. Fatty liver index (FLI) was calculated using the formula by Bedogni.
Results: Mean age at baseline: 60.9±6.0 years (T-group: 58.5±6.3, CTRL: 63.2±4.8). Mean (median) follow-up: T-group 10.1±3.0(11), CTRL 10.5±3.0(12) years. γ-GT (U/L) decreased from 45.3±26.2 to 21.1±6.8 in the T-group and increased from 34.8±11.3 to 62.0±6.9 in CTRL (p<0.0001 for both).
*Triglycerides decreased from 3.2±0.6 to 2.2±0.1 in the T-group and increased from 3.0±0.5 to 3.7±0.6 in
CTRL (p<0.0001 for both).
*Waist circumference (cm) decreased from 110.9±13.7 to 96.1±5.1 in the T- group (p<0.0001) and increased in CTRL from 111.0±11.8 to 114.3±8.3 (p<0.0001).
*BMI (kg/m²) decreased from 34.2±5.4 to 27.5±2.4 in the T-group (p<0.0001) and increased in CTRL from 30.5±4.4 to 31.6±3.4 (p<0.0001).
*AST (U/L) decreased from 39.7±15.1 to 20.7±2.0 in the T-group and increased from 26.9±8.3 to 52.7±9.8 in CTRL (p<0.0001 for both).
*ALT (U/L) decreased from 42.7±14.9 to 24.6±2.3 in the T-group and increased from 31.1±8.6 to 58.6±12.0 in CTRL (p<0.0001 for both).
*FLI decreased from 89.9±11.0 to 57.0±13.0 in the T-group and increased from 84.3±13.4 to 94.2±5.2 in CTRL (p<0.0001 for both).
Conclusion: Long-term testosterone therapy in men with functional hypogonadism improved surrogate parameters of liver function indicating an improvement in NAFLD. All parameters deteriorated in untreated controls.
